KR20090111307A - 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도 - Google Patents

전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도 Download PDF

Info

Publication number
KR20090111307A
KR20090111307A KR1020097002135A KR20097002135A KR20090111307A KR 20090111307 A KR20090111307 A KR 20090111307A KR 1020097002135 A KR1020097002135 A KR 1020097002135A KR 20097002135 A KR20097002135 A KR 20097002135A KR 20090111307 A KR20090111307 A KR 20090111307A
Authority
KR
South Korea
Prior art keywords
seq
nucleic acid
gene
sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097002135A
Other languages
English (en)
Korean (ko)
Inventor
리차드 아인스타인
케빈 폴 케인
매튜 폴 판도
Original Assignee
엑손히트 써라퓨틱스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑손히트 써라퓨틱스 에스에이 filed Critical 엑손히트 써라퓨틱스 에스에이
Publication of KR20090111307A publication Critical patent/KR20090111307A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020097002135A 2006-07-03 2007-06-29 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도 Withdrawn KR20090111307A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81768606P 2006-07-03 2006-07-03
US60/817,686 2006-07-03
PCT/EP2007/056584 WO2008003656A2 (en) 2006-07-03 2007-06-29 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics

Publications (1)

Publication Number Publication Date
KR20090111307A true KR20090111307A (ko) 2009-10-26

Family

ID=38537749

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002135A Withdrawn KR20090111307A (ko) 2006-07-03 2007-06-29 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도

Country Status (10)

Country Link
US (1) US20120141376A1 (https=)
EP (1) EP2044216A2 (https=)
JP (1) JP2009540852A (https=)
KR (1) KR20090111307A (https=)
CN (1) CN101506376A (https=)
AU (1) AU2007271232A1 (https=)
CA (1) CA2656140A1 (https=)
IL (1) IL196184A0 (https=)
WO (1) WO2008003656A2 (https=)
ZA (1) ZA200900794B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180002900A (ko) * 2009-05-12 2018-01-08 코닌클리케 필립스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
WO2018155793A1 (ko) 2017-02-23 2018-08-30 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR20200123450A (ko) * 2018-02-22 2020-10-29 리퀴드 바이옵시 리서치 엘엘씨 전립선암 검출 및 치료 방법

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
MY193914A (en) * 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
KR101698654B1 (ko) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
ES3007999T3 (en) * 2015-04-21 2025-03-21 Genentech Inc Compositions and methods for prostate cancer analysis
CA2995248A1 (en) * 2015-09-02 2017-03-09 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN111383757B (zh) * 2020-03-04 2023-08-25 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO2001055301A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
JP2005519606A (ja) * 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180002900A (ko) * 2009-05-12 2018-01-08 코닌클리케 필립스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
WO2018155793A1 (ko) 2017-02-23 2018-08-30 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
US20220106369A1 (en) 2017-02-23 2022-04-07 Sung Kyun Biotech Co., Ltd. Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same
US11498945B2 (en) 2017-02-23 2022-11-15 Sung Kyun Biotech Co., Ltd. Immunogenic fragment peptide of EN2 protein or antibody composition specifically recognizing same
US11746146B2 (en) 2017-02-23 2023-09-05 Sung Kyun Biotech Co., Ltd. Antibody composition specifically recognizing an immunogenic fragment peptide of EN2 protein
US11827696B2 (en) 2017-02-23 2023-11-28 Sung Kyun Biotech Co., Ltd. Antibody composition specifically recognizing an immunogenic fragment peptide of EN2 protein
KR20200123450A (ko) * 2018-02-22 2020-10-29 리퀴드 바이옵시 리서치 엘엘씨 전립선암 검출 및 치료 방법

Also Published As

Publication number Publication date
WO2008003656A3 (en) 2008-03-20
EP2044216A2 (en) 2009-04-08
CA2656140A1 (en) 2008-01-10
IL196184A0 (en) 2009-09-22
ZA200900794B (en) 2010-07-28
AU2007271232A1 (en) 2008-01-10
WO2008003656A2 (en) 2008-01-10
JP2009540852A (ja) 2009-11-26
CN101506376A (zh) 2009-08-12
US20120141376A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
US7834163B2 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy
KR20090111307A (ko) 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도
US6703221B1 (en) Notch receptor ligands and uses thereof
US20020051990A1 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
US20080213166A1 (en) Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
AU2003222103A8 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20090053227A1 (en) Prostate Specific Genes and The Use Thereof in Design of Therapeutics
US7442520B2 (en) Gene BRCC-3 and diagnostic and therapeutic uses thereof
US20030228317A1 (en) Gene BRCC-1 and diagnostic and therapeutic uses thereof
US20080254031A1 (en) Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
US20060134668A1 (en) Methods for treating patients and identifying therapeutics
EP1206487A2 (en) Notch receptor ligands and uses thereof
US20040161775A1 (en) Gene SHINC-1 and diagnostic and therapeutic uses thereof
US20020061552A1 (en) Mammalian dishevelled-associated proteins
JP2006519589A5 (https=)
JP2006519589A (ja) 癌における新規な組成物および方法
EP1506317B1 (en) Marker molecules associated with lung tumors
US20060089493A1 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20030186232A1 (en) Human and non-human primate homologues of Nkd protein, nucleic acid sequences encoding, and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000